Business News

Tetra Therapeutics Enters into Definitive Merger Agreement to be Acquired by Shionogi in $500 Million Deal

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–Tetra Therapeutics today announced that it has entered into a definitive merger agreement for Shionogi & Co., Ltd. to acquire Tetra. With this acquisition, Shionogi will obtain global rights to Tetra’s entire portfolio of compounds for the treatment of brain disorders associated with cognitive and memory deficits, …

Read More »

Sanofi Intends to Sell its Equity Investment in Regeneron; Confirms No Change to Ongoing Collaboration

PARIS – May 25, 2020 – Sanofi today announced its intent to sell its equity investment in Regeneron (NASDAQ: REGN) through a registered public offering and related share repurchase by Regeneron. The registered offering and share repurchase will have no impact on the ongoing collaboration between Sanofi and Regeneron. A preliminary …

Read More »

Merck Enters into COVID-19 Vaccine Race through its Acquisition of Themis

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately-held Themis. …

Read More »

ArcherDX and AstraZeneca Collaborate to Develop Personalized Cancer Monitoring Assays for Minimal Residual Disease

BOULDER, Colo., May 26, 2020 /PRNewswire/ — ArcherDX, Inc., today announced a strategic collaboration with AstraZeneca to develop assays to support multiple planned Phase 3 clinical trials for AstraZeneca’s targeted immuno-oncology therapeutics. Under the terms of the agreement, ArcherDX will perform Whole Exome Sequencing (WES) of resected non-small cell lung …

Read More »

Tavotek Enters Research Agreement with Genmab for Development of Bispecific Antibodies Using Genmab’s DuoBody Platform Against a Pair of Disease Relevant Targets

AMBLER, Pa., May 25, 2020 /PRNewswire/ — Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform against disease relevant target …

Read More »

AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera announced today that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the discovery of antibodies for up to nine Lilly-selected therapeutic targets. Lilly will have the rights to develop and commercialize therapeutic products resulting from the …

Read More »

Roche Acquires Stratos Genomics to Further Develop DNA Based Sequencing for Diagnostic Use

Basel, 22 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche’s nanopore sequencer. The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX™). The Roche nanopore sequencer, …

Read More »

AstraZeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford’s Potential New Vaccine

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s vaccine widely accessible around the world in an equitable manner. The Company has concluded the first agreements for at least 400 million …

Read More »

AbbVie and Synlogic Terminate Collaboration Agreement in IBD

CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ — Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the termination of its collaboration with AbbVie, a global, research-based biopharmaceutical company, for the development of Synthetic Biotic medicines for the potential …

Read More »

Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship

KENILWORTH, N.J. & PITTSBURGH–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and UPMC today announced that Infectious Disease Connect Inc., a UPMC-backed company offering telemedicine-enabled solutions to hospitals for treatment of infectious diseases, has combined with Merck’s ILÚM Health Solutions, a provider of technology and services to support infectious disease …

Read More »